Dietary Modulation of Neuroinflammation in Age-Related Memory Disorders

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

259 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-01-01

Study Completion Date

2023-06-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to test the effect of a cocoa-derived dietary flavanol on brain structures and cognitive outcomes in a 12-week randomized controlled trial of 146 healthy participants, age 50-69, who will receive this cocoa derivative or a placebo. Th investigators will also examine the role of inflammation in this relationship.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effects of Flavonoid Supplementation on Cognition and Neural Mechanisms in Healthy Older Adults

NCT03030053

Mental Processes

UNKNOWN NA

Investigating the Effects of Cocoa Flavanol on Cognition Assessed Online

NCT04582617

Aging Cognitive Change

COMPLETED NA

Effect of Polyphenol-rich Cocoa Products on Cognitive Function

NCT02996578

Healthy Ageing

COMPLETED NA

Effects of Cocoa Flavanols on Human Cognitive Function

NCT01344551

Neural Degeneration

COMPLETED NA

Flavanol-Rich Cocoa and Cerebral Blood Flow

NCT00825695

Hypertension Diabetes

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Within 25 years, the US population aged 65 and over will double in size to 80 million bringing, with it an epidemic of aging-related cognitive decline, from normal cognitive aging to neurodegenerative disorders including Alzheimer's Disease. These conditions impair quality of life and functional status, impose an enormous burden on individuals, their families, the healthcare system, and require elucidation of mechanisms and development of new treatments to prevent or at least slow their progression. The use of plant-based food and drink for health purposes has a long and well-documented history. Cocoa beans contain a substance that has multiple beneficial health effects. In this study, the investigators will test the effect of this substance on brain structures and cognitive outcomes in a 12-week randomized controlled trial of 146 healthy participants, age 50-69, who will receive this cocoa derivative or a placebo. The investigators also will examine the role of inflammation in this relationship. Such a trial has potential for significant clinical impact.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Memory Loss Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

650 mg of Cocoapro flavanols

Daily, each subject will consume either two cocoa flavanol-containing capsules twice a day with a meal.

Group Type ACTIVE_COMPARATOR

650 mg of Cocoapro flavanols

Intervention Type DIETARY_SUPPLEMENT

12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.

0mg Cocoapro flavanols

Daily, each subject will consume either ttwo placebo-containing capsules twice a day with a meal.

Group Type PLACEBO_COMPARATOR

0 mg of Cocoapro flavanols

Intervention Type DIETARY_SUPPLEMENT

12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

650 mg of Cocoapro flavanols

12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(650mg) twice a day with meals.

Intervention Type DIETARY_SUPPLEMENT

0 mg of Cocoapro flavanols

12-week period during which participant will be asked to consume two cocoa-flavanol-containing capsules(0mg) twice a day with meals.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal screening or management of the subject).
2. Healthy Male or Female subjects. (Females must be post-menopausal)
3. Age between 50 and 69 years, both inclusive.
4. Body mass index between 18.0 and 35 kg/m², both inclusive.

Exclusion Criteria

1. Currently undergoing medical treatment, including prescription drugs/medication.
2. Clinically significant abnormal hematology, biochemistry, urinalysis, or coagulation screening tests, as judged by the Investigator.
3. History or presence of cancer (except basal cell skin cancer or squamous cell skin cancer), or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocrinological (with the exception euthyroid struma), haematological, dermatological, venereal, neurological, psychiatric diseases or other major disorders as judged by the Investigator.
4. Seated blood pressure at screening (after resting for 5 min in seated position) outside the range of 90-140 mmHg for systolic or 50-90 mmHg for diastolic (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial) and/or resting supine heart rate outside the range 50-90 beats per minute. Measurement taken at consent before eligibility is determined
5. Heart Diseases.
6. Hepatitis B or C positive status.
7. HIV positive status.
8. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
9. Use of non-prescription medication, herbal products or nutritional supplements during the study, and within the last 4 weeks before the start of the study (screening), as judged by the Investigator; occasional use of aspirin, ibuprofen, acetaminophen is permitted.
10. Adherence to a vegan or vegetarian diet or to specialty/uncommon diets.
11. Food Allergies to tree nuts, soy, cocoa and cocoa-containing products.
12. People who choose to avoid caffeine intake.
13. Current or history of alcoholism or drug/chemical abuse as per Investigator's judgment.
14. Hormone Replacement Therapy; Currently pregnant; Pregnant or Interview\\ lactating within past 6 months; Hormonal birth control (pill).
15. Smoking.
16. Unwilling to have blood drawn or anxiety/nausea during a blood draw.
17. Uncomfortable completing memory and attention tasks in the English language
18. Montreal Cognitive Assessment (MoCA) score less than 26.
19. Inability to swallow study capsules Interview (at Consent)
20. Did not complete the two weeks Run-In Period (Participants who missed more than 2 intake occasions out of 14 days (28 occasions total) or if there are \> 8 capsules left in the bottle after the two weeks will be excluded).

MRI RELATED

1. Cardiac Pacemaker
2. Internal Pump
3. Insulin Pump
4. Tattoo eyeliner
5. Wire sutures
6. Internal Metal Objects
7. Metal Slivers in Eye
8. Prosthesis
9. Hearing Aid Implants
10. Neurostimulator
11. Metal Fragments
12. Brain Aneurysm Clips
13. Vascular Clips
14. Breast Expander
15. Vena Cava Filter
16. Heart Valve
17. Metal Stents
18. Asthmatic symptoms within the past 3 years
19. Sickle Cell Disease

Minimum Eligible Age

50 Years

Maximum Eligible Age

69 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes